One Powerful Drop
Novo Nordisk recently petitioned the FDA to ban the production of copycat drugs with semaglutides on the grounds that it is too complex a drug to be compounded, and could be potentially risky.2 Novo Nordisk and Eli Lilly (maker of Mounjaro and Zepbound) have also reaped the financial rewards of GLP-1 drugs explosion in popularity, so they have skin in the game
It slows how quickly the stomach empties, helping meals feel more satisfying and sends signals to the brain that reduce appetite
A licensed healthcare provider reviews your medical history, weight-loss goals, medications, BMI, and other health factors to determine whether Tirzepatide, Zepbound, or another treatment option may be appropriate
When paired with education, nutrition guidance, and realistic expectations, it becomes less about losing weight and more about regaining control and confidence
She notes that "when people [generally] lose even a small amount of weight and improve their metabolic health, their risk of depression and anxiety goes down." This pattern existed before what she calls the "Ozempic revolution." In 2024, following an uptick in reports of suicidal thoughts and behaviors associated with GLP-1 use, the U.S
